A revolutionary blood-based diagnostic test measures three kinase signaling pathway activities to determine the likelihood of the patient having ASD at an early stage.
According to the CDC, 1 in 68 children has been identified with ASD. However, most autism children are not diagnosed until after the age of four through a series of behavioral evaluations. This delay in diagnosis can prevent the child from benefiting from early intervention therapies, which have been shown to reduce the severity of the disorder by improving brain function and behavior. Since there are no blood-based diagnostics available on the market, this simple and accurate test for ASD could revolutionize the field.
Alterations in protein kinase signaling activities seen in the brain tissue of ASD animal models can also be observed in the readily accessible peripheral blood cells. This opens the exciting door for using a blood test to assess the likelihood of having ASD. The inventors have correlated three signaling protein kinase activities, measurable in the blood. This invention measures the activity levels of these pathways and compiles these measurements into a patent-pending diagnostic formula which is validated on human patient samples.
To develop and commercialize the technology to early screen and diagnose children for autism spectrum disorders
Animal data and human autism patient data available
|United States Of America||Issued Patent||10,941,194||03/09/2021||2014-052|